RecruitingNCT07794774Updated Nov 6, 2026

A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)

A Phase 3 interventional study of Berobenatide and Placebo in Obesity, sponsored by Pfizer. Recruiting at 36 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

From the registry’s dates

Started Sep 2026; still recruiting 1 month later.

Updated Nov 6, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Status

Not yet recruiting→Recruiting

changed Nov 6, 2026

Sites

25 sites added. 28 sites changed recruiting status (27 now recruiting, 1 now not yet recruiting)

Show 28 sites

Tenjin Sogo Clinic · Fukuoka, Japanno status→Recruiting
Medical Corporation BOOCS BOOCS CLINIC FUKUOKA · Fukuoka, Japanno status→Recruiting
Oishi Clinic · Kasuya-gun, Japanno status→Recruiting
Manda Memorial Hospital · Sapporo, Japanno status→Recruiting
Yamasaki Family Clinic · Amagasaki, Japanno status→Recruiting
Minami Akatsuka Clinic · Mito, Japanno status→Not yet recruiting
Nishiyamado Keiwa Hospital · Naka, Japanno status→Recruiting
Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic · Yokohama, Japanno status→Recruiting
Yokoi Clinic · Minoh, Japanno status→Recruiting
Kanemura Clinic · Osaka-shi Ikuno-ku, Japanno status→Recruiting
Medical Corporation Heishinkai OCROM Clinic · Suita, Japanno status→Recruiting
MI Clinic, Medical Corporation Jinsenkai · Toyonaka-shi, Japanno status→Recruiting
Soka Sugiura Internal medicine Clinic · Soka-shi, Japanno status→Recruiting
Aic Yaesu Clinic · Chuo-ku, Japanno status→Recruiting
Tokyo Center Clinic · Chuo-ku, Japanno status→Recruiting
Tokyo-Eki Center-building Clinic · Chuo-ku, Japanno status→Recruiting
Fukuwa Clinic · Chuo-ku, Japanno status→Recruiting
Tokyo Asbo Clinic · Chuo-ku, Japanno status→Recruiting
Medical Corp. Seikoukai New Medical Research System Clinic · Hachioji-shi, Japanno status→Recruiting
Hachioji Clinic Shincho · Hachioji-shi, Japanno status→Recruiting
Keikokai Medical Corporation P-one Clinic · Hachiōji, Japanno status→Recruiting
Patient First Clinic Ginza-Shimbashi · Minato-ku, Japanno status→Recruiting
Shimamura Memorial Hospital · Nerima-ku, Japanno status→Recruiting
Medical Corporation Heishinkai ToCROM Clinic · Shinjuku-ku, Japanno status→Recruiting
Seeds Clinic Shinjuku-Sanchome, Eijinkai Medical Corporation · Shinjuku-ku, Japanno status→Recruiting
Higashi-Shinjuku Clinic, Keikokai Medical Corp. · Shinjuku-ku, Japanno status→Recruiting
Ikebukuro Metropolitan Clinic · Toshima-ku, Japanno status→Recruiting
Nihonbashi Sakura Clinic · Tokyo, Japanno status→Recruiting

Show 25 added (25 Japan)

Tenjin Sogo Clinic · Fukuoka, Japan
Medical Corporation BOOCS BOOCS CLINIC FUKUOKA · Fukuoka, Japan
Yamasaki Family Clinic · Amagasaki, Japan
Minami Akatsuka Clinic · Mito, Japan
Nishiyamado Keiwa Hospital · Naka, Japan
Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic · Yokohama, Japan
Yokoi Clinic · Minoh, Japan
Kanemura Clinic · Osaka-shi Ikuno-ku, Japan
MI Clinic, Medical Corporation Jinsenkai · Toyonaka-shi, Japan
Soka Sugiura Internal medicine Clinic · Soka-shi, Japan
Aic Yaesu Clinic · Chuo-ku, Japan
Tokyo Asbo Clinic · Chuo-ku, Japan
Medical Corp. Seikoukai New Medical Research System Clinic · Hachioji-shi, Japan
Hachioji Clinic Shincho · Hachioji-shi, Japan
Keikokai Medical Corporation P-one Clinic · Hachiōji, Japan
Patient First Clinic Ginza-Shimbashi · Minato-ku, Japan
Seeds Clinic Shinjuku-Sanchome, Eijinkai Medical Corporation · Shinjuku-ku, Japan
Tokuyama Clinic · Mihama-ku, Japan
Mikannohana Clinic, Diabetes, Endocrinology and Metabolism · Matsuyama, Japan
Matsuyama Shimin Hospital · Matsuyama, Japan
Fukuoka Diagnostic Imaging Clinic Me-Well · Fukuoka, Japan
Mito Saiseikai General Hospital · Mito, Japan
Olive Takamatsu Medical Clinic · Takamatsu, Japan
Saiyu Soka Hospital · Soka-shi, Japan
Doujin Memorial Foundation Meiwa Hospital · Chiyoda-ku, Japan

across 2 updates, Sep 25, 2026 – Nov 6, 2026

Start date

Sep 28, 2026→Sep 29, 2026 (actual)

Nov 6, 2026

Phase: Phase 3
Study type: Interventional
Enrollment: 197
Allocation: Randomized
Ages: 18 Years and older
Sex: All

Where this study stands

Counted across the records on this site · 2026-11-12

Among 20 studies testing berobenatide in Obesity — 10 open to participants now, 14 under way, 11 of them phase 3. berobenatide · Obesity.

Planned enrollment: 13th of 20; 197 · median 249
Started: 2026; with 13 others
Phase 3: 11 of 20; 9 open now
Primary completion: 2029-02; later than 12 of 13 live
Registered: 12th of 20; by date
Lead sponsor: 19 of 20; Pfizer

Among the 20 studies testing berobenatide in Obesity, this one is the 13th largest by planned enrollment, is one of 14 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 12 of the 13 other live ones, and was the 12th registered.

By phase

20 studies; the count open now beside each. This study's row is marked.

Phase 3this study11 · 9 open

Phase 14 · 1 open

Phase 23 · 0 open

Phase 1/22 · 0 open

By the year they started

224

425

1426

First in 2024; this study’s year is marked. 14 started in 2026.

Tested beside berobenatide

Acetaminophen1

Size and results

Median enrollment 249 across the 20 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.

Who runs the 20 studies testing berobenatide in Obesity

20 of 20 have an industry lead sponsor. The 2 most frequent:

Pfizer19 · 10 open · industry

Metsera, a wholly owned subsidiary of Pfizer1 · industry

Pfizer in Obesity

Pfizer is the lead sponsor of 3,334 studies on the registry; 149 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.

61 studies in Obesity by Pfizer: 12 open now, 18 under way, 11 of them phase 3. Of 41 finished, 11 (27%) have results posted.

Among the 61 studies in Obesity by Pfizer, this one is the 24th largest by planned enrollment of the 60 interventional ones, is one of 18 that started in 2026, is one of 15 in phase 3, reaches primary completion later than 16 of the 17 other live ones, and was the 52nd registered.

104

105

606

607

408

109

111

113

114

117

320

321

122

223

624

525

1826

Pfizer’s Obesity studies by the year they started, since 2004.

Its medicines here

Browse Pfizer studies →Its Obesity studies →

Coming up

5 of the studies testing berobenatide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:

Study	Primary completion
NCT07311850Phase 3PfizerEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity	2027-09-21
NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)	2027-10-12
NCT07508241PfizerA Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity	2027-01-27
NCT07845513PfizerA Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity	2027-02-21
NCT07876531PfizerA Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity	2027-04-06

What changed since 2026-09-25

Among the 20 studies testing berobenatide in Obesity, from their registry updates:

Newly registered 6

NCT079196782026-11-05A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
NCT079156092026-11-04A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
NCT078746332026-10-15A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
NCT078765312026-10-15A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
NCT078455002026-09-29A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

1 more — sign in →

Started recruiting 7

NCT077947742026-11-06A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)
NCT078746332026-11-06A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
NCT078765312026-11-06A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
NCT077947612026-10-15A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)
NCT078455002026-10-15A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

2 more — sign in →

Primary completion moved 2

NCT069243202026-11-022026-09-15 → 2026-09-29A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
NCT078236082026-09-292028-06-19 → 2028-04-30A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)

Among Pfizer’s 61 in Obesity:

Newly registered 7

NCT079196782026-11-05A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
NCT079156092026-11-04A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
NCT078746332026-10-15A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
NCT078765312026-10-15A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
NCT078765182026-10-15A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity

2 more — sign in →

Started recruiting 7

NCT077947742026-11-06A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)
NCT078765312026-11-06A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
NCT078746332026-11-06A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
NCT077929542026-10-15A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
NCT077947612026-10-15A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)

2 more — sign in →

Primary completion moved 2

NCT069243202026-11-022026-09-15 → 2026-09-29A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
NCT078236082026-09-292028-06-19 → 2028-04-30A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)

Watch this landscape Download CSVWith an account: a weekly mail of what changed among 20 studies testing berobenatide in Obesity, or all of them as a file.

Study summary

The purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition in which a person has too much body fat, which can harm their health and increase the risk of other medical problems. Some participants in this study may also have type 2 diabetes, a condition in which the body does not use insulin properly, causing blood sugar levels to become too high.

This study is seeking participants in Japan who:

Have obesity disease.
May have type 2 diabetes.
Meet the study-specific age, weight, and health requirements.

About 197 adults will take part in this study. Participants will be randomly assigned to receive either berobenatide or a placebo. A placebo looks like the study medicine but does not contain any active medicine.

Berobenatide or placebo will be given as an injection under the skin of the abdomen (belly area). The study will compare the experiences of people receiving berobenatide with those receiving placebo to determine whether berobenatide can help people lose weight. The study will also assess the safety of berobenatide and its effects on body weight and other health measures.

People will take part in this study for about 21 months. During this time, they will have about 16 study visits at the site. They will also have 2 study visits over the phone.

Conditions studied

Obesity

Browse trials for

Keywords

obesity
overweight
obesity disease

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Aged ≥18 years.
of: ≥27.0 kg/m2 to \<35.0 kg/m2 with ≥2 obesity-related health disorders or BMI of ≥35.0 kg/m2 with ≥1 obesity-related health disorder. The participant must have at least one of either hypertension, dyslipidemia or glucose intolerance (T2D and impaired glucose tolerance etc.) as an obesity-related health disorder.

Exclusion criteria

Exclusion Criteria:

Have a self-reported body weight change greater than 5% within 90 days prior to Screening.
Diagnosis of type 1 diabetes or any other form of diabetes other than T2D.
History of acute or chronic pancreatitis.
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Study design

Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Triple (Participant, Care provider, Investigator)
Enrollment: 197 participants (estimated)

Study arms

Experimental
Treatment Arm 1
Participants will receive berobenatide solution for injection as subcutaneous injection.
Drug: Berobenatide
Experimental
Placebo
Participants will receive placebo solution for injection as subcutaneous injection.
Other: Placebo
Experimental
Treatment Arm 2
Participants will receive berobenatide solution for injection as subcutaneous injection.
Drug: Berobenatide
Experimental
Treatment Arm 3
Participants will receive berobenatide solution for injection as subcutaneous injection.
Drug: Berobenatide
Experimental
Treatment Arm 4
Participants will receive berobenatide solution for injection as subcutaneous injection.
Drug: Berobenatide

Interventions

DrugBerobenatide
Subcutaneous Injection
Also known as: MET097, PF-08653944
OtherPlacebo
Subcutaneous Injection

What researchers measure

Primary outcomes

Percent change from baseline in body weight
Time frame: Baseline, Week 72

Secondary outcomes

Change from baseline in waist circumference
Time frame: Baseline, Week 72
Percentage of participants achieving ≥10% of body weight reduction from baseline
Time frame: Baseline, Week 72
Percentage of participants achieving ≥15% of body weight reduction from baseline
Time frame: Baseline, Week 72
Percentage of participants achieving ≥20% of body weight reduction from baseline
Time frame: Baseline, Week 72
Percentage of participants achieving ≥5% of body weight reduction from baseline
Time frame: Baseline, Week 72
Change from baseline in body weight
Time frame: Baseline, Week 72
Change from baseline in Systolic Blood Pressure (SBP)
Time frame: Baseline, Week 72
Change from baseline in Diastolic Blood Pressure (DBP)
Time frame: Baseline, Week 72
Change from baseline in Impact of Weight on Quality of Life-Lite-Clinical Trial (IWQoL-Lite-CT) Physical Function composite score
Time frame: Baseline, Week 72
Change from baseline in IWQoL-Lite-CT total score
Time frame: Baseline, Week 72
Change from baseline in IWQoL-Lite-CT Physical composite score
Time frame: Baseline, Week 72
Change from baseline in IWQoL-Lite-CT Psychosocial composite score
Time frame: Baseline, Week 72
Change from baseline in fasting glucose
Time frame: Baseline, Week 72
Change from baseline in fasting insulin
Time frame: Baseline, Week 72
Change from baseline in revised Homeostatic Model Assessment insulin sensitivity as a percentage of normal (HOMA2-%S)
Time frame: Baseline, Week 72
Change from baseline in revised Homeostatic Model Assessment beta-cell function as a percentage of a normal reference population (HOMA2-%B)
Time frame: Baseline, Week 72
Change from baseline in HbA1c
Time frame: Baseline, Week 72
Change from baseline in fasting total cholesterol
Time frame: Baseline, Week 72
Change from baseline in fasting low-density lipoprotein cholesterol
Time frame: Baseline, Week 72
Change from baseline in fasting very low-density lipoprotein cholesterol
Time frame: Baseline, Week 72
Change from baseline in fasting non-high-density lipoprotein cholesterol
Time frame: Baseline, Week 72
Change from baseline in fasting high-density lipoprotein cholesterol
Time frame: Baseline, Week 72
Change from baseline in fasting triglycerides
Time frame: Baseline, Week 72
Change from baseline in high-sensitivity C-reactive protein
Time frame: Baseline, Week 72
Change from baseline in interleukin-6
Time frame: Baseline, Week 72
Change from baseline in interleukin-1 beta
Time frame: Baseline, Week 72
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Time frame: Week 72
Number of participants with Serious Adverse Events (SAEs)
Time frame: Week 72
Number of participants with adverse events leading to discontinuation
Time frame: Week 72
Number of participants with Adverse Events of Special Interest (AESIs)
Time frame: Week 72
Number of participants with absolute and change from baseline in laboratory measurements
Time frame: Week 72
Change from baseline in visceral fat area
Time frame: Baseline, Week 72
Percentage of participants achieving visceral fat area <100 cm2
Time frame: Week 72
Percentage of participants achieving the conversion to normoglycemia
Time frame: Week 72
Change from baseline in Oral Glucose Tolerance Test (OGTT) 2h
Time frame: Baseline, Week 72
Percentage of participants achieving conversion from HbA1c ≥7% to HbA1c <7%
Time frame: Week 72
Percentage of participants achieving conversion from HbA1c ≥5.7% to HbA1c <5.7%
Time frame: Week 72

Study locations

34 of 36 sites recruiting

Tokuyama Clinic
Mihama-ku, Chiba 261-0004, Japan
2 other open studies at this site →
Recruiting
Recruiting
Mikannohana Clinic, Diabetes, Endocrinology and Metabolism
Matsuyama, Ehime 790-0034, Japan
3 other open studies at this site →
Recruiting
Recruiting
Matsuyama Shimin Hospital
Matsuyama, Ehime 790-0067, Japan
3 other open studies at this site →
Recruiting
Recruiting
Tenjin Sogo Clinic
Fukuoka, Fukuoka 810-0021, Japan
2 other open studies at this site →
Recruiting
Recruiting
Medical Corporation BOOCS BOOCS CLINIC FUKUOKA
Fukuoka, Fukuoka 812-0025, Japan
1 other open study at this site →
Recruiting
Recruiting
Fukuoka Diagnostic Imaging Clinic Me-Well
Fukuoka, Fukuoka 812-0039, Japan
1 other open study at this site →
Recruiting
Recruiting
Oishi Clinic
Kasuya-gun, Fukuoka 811-2310, Japan
2 other open studies at this site →
Recruiting
Recruiting
Manda Memorial Hospital
Sapporo, Hokkaido 060-0062, Japan
2 other open studies at this site →
Recruiting
Recruiting
Yamasaki Family Clinic
Amagasaki, Hyōgo 660- 0861, Japan
2 other open studies at this site →
Recruiting
Recruiting
Minami Akatsuka Clinic
Mito, Ibaraki 311-4153, Japan
1 other open study at this site →
Not yet recruiting
Not yet recruiting
Mito Saiseikai General Hospital
Mito, Ibaraki 311-4198, Japan
3 other open studies at this site →
Not yet recruiting
Not yet recruiting
Nishiyamado Keiwa Hospital
Naka, Ibaraki 311-0133, Japan
1 other open study at this site →
Recruiting
Recruiting
Olive Takamatsu Medical Clinic
Takamatsu, Kagawa-ken 760-0076, Japan
1 other open study at this site →
Recruiting
Recruiting
Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic
Yokohama, Kanagawa 231-0023, Japan
2 other open studies at this site →
Recruiting
Recruiting
Yokoi Clinic
Minoh, Osaka 562-0003, Japan
2 other open studies at this site →
Recruiting
Recruiting
Kanemura Clinic
Osaka-shi Ikuno-ku, Osaka 544-0004, Japan
1 other open study at this site →
Recruiting
Recruiting
Medical Corporation Heishinkai OCROM Clinic
Suita, Osaka 565-0853, Japan
9 other open studies at this site →
Recruiting
Recruiting
MI Clinic, Medical Corporation Jinsenkai
Toyonaka-shi, Osaka 560-0004, Japan
1 other open study at this site →
Recruiting
Recruiting
Soka Sugiura Internal medicine Clinic
Soka-shi, Saitama 340-0015, Japan
3 other open studies at this site →
Recruiting
Recruiting
Saiyu Soka Hospital
Soka-shi, Saitama 340-0041, Japan
1 other open study at this site →
Recruiting
Recruiting
Doujin Memorial Foundation Meiwa Hospital
Chiyoda-ku, Tokyo 101-0041, Japan
2 other open studies at this site →
Recruiting
Recruiting
Aic Yaesu Clinic
Chuo-ku, Tokyo 103-0027, Japan
1 other open study at this site →
Recruiting
Recruiting
Tokyo Center Clinic
Chuo-ku, Tokyo 103-0027, Japan
3 other open studies at this site →
Recruiting
Recruiting
Tokyo-Eki Center-building Clinic
Chuo-ku, Tokyo 103-0027, Japan
9 other open studies at this site →
Recruiting
Recruiting
Fukuwa Clinic
Chuo-ku, Tokyo 104-0031, Japan
11 other open studies at this site →
Recruiting
Recruiting
Tokyo Asbo Clinic
Chuo-ku, Tokyo 104-0031, Japan
4 other open studies at this site →
Recruiting
Recruiting
Medical Corp. Seikoukai New Medical Research System Clinic
Hachioji-shi, Tokyo 192-0046, Japan
2 other open studies at this site →
Recruiting
Recruiting
Hachioji Clinic Shincho
Hachioji-shi, Tokyo 192-0065, Japan
1 other open study at this site →
Recruiting
Recruiting
Keikokai Medical Corporation P-one Clinic
Hachiōji, Tokyo 192-0071, Japan
1 other open study at this site →
Recruiting
Recruiting
Patient First Clinic Ginza-Shimbashi
Minato-ku, Tokyo 105-0004, Japan
2 other open studies at this site →
Recruiting
Recruiting
Shimamura Memorial Hospital
Nerima-ku, Tokyo 177-0051, Japan
3 other open studies at this site →
Recruiting
Recruiting
Medical Corporation Heishinkai ToCROM Clinic
Shinjuku-ku, Tokyo 160-0008, Japan
4 other open studies at this site →
Recruiting
Recruiting
Seeds Clinic Shinjuku-Sanchome, Eijinkai Medical Corporation
Shinjuku-ku, Tokyo 160-0022, Japan
1 other open study at this site →
Recruiting
Recruiting
Higashi-Shinjuku Clinic, Keikokai Medical Corp.
Shinjuku-ku, Tokyo 169-0072, Japan
1 other open study at this site →
Recruiting
Recruiting
Ikebukuro Metropolitan Clinic
Toshima-ku, Tokyo 171-0021, Japan
1 other open study at this site →
Recruiting
Recruiting
Nihonbashi Sakura Clinic
Tokyo, 103-0025, Japan
3 other open studies at this site →
Recruiting
Recruiting

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

Updates

2 registry updates since Sep 25, 2026

Status

Not yet recruiting→Recruiting

changed Nov 6, 2026

Sites

25 sites added. 28 sites changed recruiting status (27 now recruiting, 1 now not yet recruiting)

Show 28 sites

Tenjin Sogo Clinic · Fukuoka, Japanno status→Recruiting
Medical Corporation BOOCS BOOCS CLINIC FUKUOKA · Fukuoka, Japanno status→Recruiting
Oishi Clinic · Kasuya-gun, Japanno status→Recruiting
Manda Memorial Hospital · Sapporo, Japanno status→Recruiting
Yamasaki Family Clinic · Amagasaki, Japanno status→Recruiting
Minami Akatsuka Clinic · Mito, Japanno status→Not yet recruiting
Nishiyamado Keiwa Hospital · Naka, Japanno status→Recruiting
Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic · Yokohama, Japanno status→Recruiting
Yokoi Clinic · Minoh, Japanno status→Recruiting
Kanemura Clinic · Osaka-shi Ikuno-ku, Japanno status→Recruiting
Medical Corporation Heishinkai OCROM Clinic · Suita, Japanno status→Recruiting
MI Clinic, Medical Corporation Jinsenkai · Toyonaka-shi, Japanno status→Recruiting
Soka Sugiura Internal medicine Clinic · Soka-shi, Japanno status→Recruiting
Aic Yaesu Clinic · Chuo-ku, Japanno status→Recruiting
Tokyo Center Clinic · Chuo-ku, Japanno status→Recruiting
Tokyo-Eki Center-building Clinic · Chuo-ku, Japanno status→Recruiting
Fukuwa Clinic · Chuo-ku, Japanno status→Recruiting
Tokyo Asbo Clinic · Chuo-ku, Japanno status→Recruiting
Medical Corp. Seikoukai New Medical Research System Clinic · Hachioji-shi, Japanno status→Recruiting
Hachioji Clinic Shincho · Hachioji-shi, Japanno status→Recruiting
Keikokai Medical Corporation P-one Clinic · Hachiōji, Japanno status→Recruiting
Patient First Clinic Ginza-Shimbashi · Minato-ku, Japanno status→Recruiting
Shimamura Memorial Hospital · Nerima-ku, Japanno status→Recruiting
Medical Corporation Heishinkai ToCROM Clinic · Shinjuku-ku, Japanno status→Recruiting
Seeds Clinic Shinjuku-Sanchome, Eijinkai Medical Corporation · Shinjuku-ku, Japanno status→Recruiting
Higashi-Shinjuku Clinic, Keikokai Medical Corp. · Shinjuku-ku, Japanno status→Recruiting
Ikebukuro Metropolitan Clinic · Toshima-ku, Japanno status→Recruiting
Nihonbashi Sakura Clinic · Tokyo, Japanno status→Recruiting

Show 25 added (25 Japan)

Tenjin Sogo Clinic · Fukuoka, Japan
Medical Corporation BOOCS BOOCS CLINIC FUKUOKA · Fukuoka, Japan
Yamasaki Family Clinic · Amagasaki, Japan
Minami Akatsuka Clinic · Mito, Japan
Nishiyamado Keiwa Hospital · Naka, Japan
Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic · Yokohama, Japan
Yokoi Clinic · Minoh, Japan
Kanemura Clinic · Osaka-shi Ikuno-ku, Japan
MI Clinic, Medical Corporation Jinsenkai · Toyonaka-shi, Japan
Soka Sugiura Internal medicine Clinic · Soka-shi, Japan
Aic Yaesu Clinic · Chuo-ku, Japan
Tokyo Asbo Clinic · Chuo-ku, Japan
Medical Corp. Seikoukai New Medical Research System Clinic · Hachioji-shi, Japan
Hachioji Clinic Shincho · Hachioji-shi, Japan
Keikokai Medical Corporation P-one Clinic · Hachiōji, Japan
Patient First Clinic Ginza-Shimbashi · Minato-ku, Japan
Seeds Clinic Shinjuku-Sanchome, Eijinkai Medical Corporation · Shinjuku-ku, Japan
Tokuyama Clinic · Mihama-ku, Japan
Mikannohana Clinic, Diabetes, Endocrinology and Metabolism · Matsuyama, Japan
Matsuyama Shimin Hospital · Matsuyama, Japan
Fukuoka Diagnostic Imaging Clinic Me-Well · Fukuoka, Japan
Mito Saiseikai General Hospital · Mito, Japan
Olive Takamatsu Medical Clinic · Takamatsu, Japan
Saiyu Soka Hospital · Soka-shi, Japan
Doujin Memorial Foundation Meiwa Hospital · Chiyoda-ku, Japan

across 2 updates, Sep 25, 2026 – Nov 6, 2026

Start date

Sep 28, 2026→Sep 29, 2026 (actual)

Nov 6, 2026

Show all 2 updates

Nov 6, 2026
Not yet recruiting→Recruiting
8 sites added. 28 sites changed recruiting status (27 now recruiting, 1 now not yet recruiting)
Show 28 sites
- Tenjin Sogo Clinic · Fukuoka, Japanno status→Recruiting
- Medical Corporation BOOCS BOOCS CLINIC FUKUOKA · Fukuoka, Japanno status→Recruiting
- Oishi Clinic · Kasuya-gun, Japanno status→Recruiting
- Manda Memorial Hospital · Sapporo, Japanno status→Recruiting
- Yamasaki Family Clinic · Amagasaki, Japanno status→Recruiting
- Minami Akatsuka Clinic · Mito, Japanno status→Not yet recruiting
- Nishiyamado Keiwa Hospital · Naka, Japanno status→Recruiting
- Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic · Yokohama, Japanno status→Recruiting
- Yokoi Clinic · Minoh, Japanno status→Recruiting
- Kanemura Clinic · Osaka-shi Ikuno-ku, Japanno status→Recruiting
- Medical Corporation Heishinkai OCROM Clinic · Suita, Japanno status→Recruiting
- MI Clinic, Medical Corporation Jinsenkai · Toyonaka-shi, Japanno status→Recruiting
- Soka Sugiura Internal medicine Clinic · Soka-shi, Japanno status→Recruiting
- Aic Yaesu Clinic · Chuo-ku, Japanno status→Recruiting
- Tokyo Center Clinic · Chuo-ku, Japanno status→Recruiting
- Tokyo-Eki Center-building Clinic · Chuo-ku, Japanno status→Recruiting
- Fukuwa Clinic · Chuo-ku, Japanno status→Recruiting
- Tokyo Asbo Clinic · Chuo-ku, Japanno status→Recruiting
- Medical Corp. Seikoukai New Medical Research System Clinic · Hachioji-shi, Japanno status→Recruiting
- Hachioji Clinic Shincho · Hachioji-shi, Japanno status→Recruiting
- Keikokai Medical Corporation P-one Clinic · Hachiōji, Japanno status→Recruiting
- Patient First Clinic Ginza-Shimbashi · Minato-ku, Japanno status→Recruiting
- Shimamura Memorial Hospital · Nerima-ku, Japanno status→Recruiting
- Medical Corporation Heishinkai ToCROM Clinic · Shinjuku-ku, Japanno status→Recruiting
- Seeds Clinic Shinjuku-Sanchome, Eijinkai Medical Corporation · Shinjuku-ku, Japanno status→Recruiting
- Higashi-Shinjuku Clinic, Keikokai Medical Corp. · Shinjuku-ku, Japanno status→Recruiting
- Ikebukuro Metropolitan Clinic · Toshima-ku, Japanno status→Recruiting
- Nihonbashi Sakura Clinic · Tokyo, Japanno status→Recruiting
Show 8 added (8 Japan)
- Tokuyama Clinic · Mihama-ku, Japan
- Mikannohana Clinic, Diabetes, Endocrinology and Metabolism · Matsuyama, Japan
- Matsuyama Shimin Hospital · Matsuyama, Japan
- Fukuoka Diagnostic Imaging Clinic Me-Well · Fukuoka, Japan
- Mito Saiseikai General Hospital · Mito, Japan
- Olive Takamatsu Medical Clinic · Takamatsu, Japan
- Saiyu Soka Hospital · Soka-shi, Japan
- Doujin Memorial Foundation Meiwa Hospital · Chiyoda-ku, Japan
Start date Sep 28, 2026→Sep 29, 2026 (now actual)
+ 1 other change: verification date
Sep 25, 2026
17 sites added
Show 17 added (17 Japan)
- Tenjin Sogo Clinic · Fukuoka, Japan
- Medical Corporation BOOCS BOOCS CLINIC FUKUOKA · Fukuoka, Japan
- Yamasaki Family Clinic · Amagasaki, Japan
- Minami Akatsuka Clinic · Mito, Japan
- Nishiyamado Keiwa Hospital · Naka, Japan
- Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic · Yokohama, Japan
- Yokoi Clinic · Minoh, Japan
- Kanemura Clinic · Osaka-shi Ikuno-ku, Japan
- MI Clinic, Medical Corporation Jinsenkai · Toyonaka-shi, Japan
- Soka Sugiura Internal medicine Clinic · Soka-shi, Japan
- Aic Yaesu Clinic · Chuo-ku, Japan
- Tokyo Asbo Clinic · Chuo-ku, Japan
- Medical Corp. Seikoukai New Medical Research System Clinic · Hachioji-shi, Japan
- Hachioji Clinic Shincho · Hachioji-shi, Japan
- Keikokai Medical Corporation P-one Clinic · Hachiōji, Japan
- Patient First Clinic Ginza-Shimbashi · Minato-ku, Japan
- Seeds Clinic Shinjuku-Sanchome, Eijinkai Medical Corporation · Shinjuku-ku, Japan

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT07794774
Lead sponsor: Pfizer
Responsible party: Sponsor
First posted: Aug 31, 2026
Start date: Sep 29, 2026
Primary completion: Feb 21, 2029 (estimated)
Completion: Feb 21, 2029 (estimated)
Last update: Nov 6, 2026

Study contacts

Pfizer CT.gov Call Center

Contact

ClinicalTrials.gov_Inquiries@pfizer.com

1-800-718-1021

Pfizer CT.gov Call Center

study director · Pfizer

Oversight

Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berobenatide

Other studies in this condition

Obesity →

Other studies from this sponsor

Pfizer →

Start the discussion

A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)

From the registry’s dates

Where this study stands

Obesity

Open to participants now

Where they have run

About berobenatide

Who these studies take

By phase

By the year they started

Tested beside berobenatide

Size and results

Who runs the 20 studies testing berobenatide in Obesity

Pfizer in Obesity

Its medicines here

Coming up

What changed since 2026-09-25

Newly registered 6

Started recruiting 7

Primary completion moved 2

Newly registered 7

Started recruiting 7

Primary completion moved 2

Study summary

Conditions studied

Browse trials for

Keywords

Who can participate

✓Inclusion criteria

✕Exclusion criteria

Study design

Study arms

Interventions

What researchers measure

Primary outcomes

Secondary outcomes

Study locations

References and documents

Related links

Individual participant data

Updates

Registry details

Key details

Study contacts

Oversight

Interested in this study?

Follow this study

Discussion

Other studies in this condition

Other studies from this sponsor

Inclusion criteria

Exclusion criteria